5 results about "Elevated serum" patented technology

The invention discloses construction and application of a Primrose syndrome non-human animal model, and belongs to the technical field of animal models and disease research. According to the invention, through a CRISPR / Cas9 technology, a codon CAC for coding 596th histidine in a No.14 exon of a mouse Zbtb20 gene is subjected to site-directed mutagenesis into CGC for coding arginine, and a hybrid mouse model for simulating pathogenic point mutation (p.H596R) of human Primrose syndrome is constructed. The model can stably reproduce key clinical phenotypes of the Primrose syndrome, including overgrowth after adult, serum IGF-1 rise, memory dysfunction and anxiety behaviors, and shows abnormal hippocampal neuronal development and synaptic transfer related pathways and the like. The invention provides an important experimental tool for deeply revealing the pathological mechanism of Primrose syndrome, developing drug screening and treatment intervention research and the like.

The application provides an optimized lactoferricin peptide, a preparation method thereof and application thereof in preparation of anti-inflammatory and anti-oxidative damage preparations, and belongs to the technical field of biological medicines.The application obtains high-biological-activity lactoferricin peptide by optimizing amino acid sites of lactoferricin B; compared with the original lactoferricin B, the optimized lactoferricin peptide has better anti-inflammatory and anti-oxidative effects, can effectively reduce alcohol-induced oxidative damage, fatty degeneration and apoptosis of liver cells, and promote recovery of liver function.The lactoferricin peptide provided by the application can reduce the elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels by about 25% and 20%, respectively.The application provides an application scheme in development of a new generation of polypeptide drugs for treating alcoholic liver disease, hepatitis, acute lung injury and various inflammation oxidative stress related diseases.

The present invention relates to compositions comprising microorganisms for use in the reduction of blood urate concentration. These compositions can be used for the therapeutic and the preventive treatment of subjects at risk or suffering from elevated blood urate levels. The compositions can be pharmaceutical compositions or nutraceutical composition 5 that are used for treatment and prevention of urate and hyperuricemia associated diseases such as cardiovascular disease, metabolic syndrome, non-alcoholic fatty liver disease, chronic kidney disease, gout, insulin resistance, hypertension, dyslipidaemia, renal insufficiency, obesity, pre-diabetes and diabetes.

In the present invention, inventors shows that exposure to high AMH levels during mini-puberty in mice causes PCOS-like reproductive and metabolic defects in both sexes. Inventors designed and developed several neutralizing antibodies against AMH receptor 2 (AMHR2) and discovered that administering the neutralizing antibody Ha13 during mini-puberty to a preclinical model of PCOS termed PAMH, which retains high circulating AMH levels, prevents the appearance of reproductive and metabolic abnormalities in adulthood. These findings suggest that exposure to elevated serum AMH levels during early postnatal life plays a causal role in the pathophysiology of PCOS. They also demonstrate the promise of AMHR2-targeting therapy in preventing both the onset and inheritance of PCOS-traits. Accordingly, the invention relates to new neutralizing antibodies that specifically binds with high affinity AMHR2, especially the epitope region involved in the interaction with the natural ligand AMH. Thus, these specific antibodies can be used for the prevention and / or therapy of polycystic ovary syndrome (PCOS).

The invention belongs to the technical field of functional microorganisms and application thereof, and relates to compound lactic acid bacteria and application thereof in preparation of products for relieving hyperuricemia. The compound lactobacillus is prepared from lactobacillus plantarum PL4-9, pediococcus acidilactici FB1-3 and lactobacillus plantarum sc3-2, and the preservation numbers of the lactobacillus plantarum PL4-9, the pediococcus acidilactici FB1-3 and the lactobacillus plantarum sc3-2 are CGMCC (China General Microbiological Culture Collection Center) NO. 34075, CGMCC NO. 34076 and The compound lactic acid bacteria formed by mixing the raw materials according to the volume ratio of 1: 1: 1 can obviously reduce the serum uric acid and urea nitrogen level of a mouse with hyperuricemia, and also has an obvious relieving effect on abnormal increase of serum xanthine oxidase activity; the generation of uric acid can be reduced by inhibiting the activity of liver xanthine oxidase, and meanwhile, the liver and kidney injury induced by hyperuricemia can be remarkably relieved.